<DOC>
	<DOCNO>NCT02096705</DOCNO>
	<brief_summary>The purpose determine 24 week oral daily administration , great mean reduction baseline glycosylated hemoglobin ( HbA1c ) achieve Dapagliflozin 10 mg plus insulin compare placebo plus insulin subject type 2 diabetes .</brief_summary>
	<brief_title>Phase III Insulin Add-On Asia Regional Program - ST</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects must type 2 diabetes inadequate glycemic control , define HbA1c ≥ 7.5 % ≤ 11.0 % obtain screen visit Subjects must take stable mean dose ≥ 20 IU injectable insulin daily least 8 week prior enrollment Treatment two oral antidiabetic ( OAD ) agent within 6 week Enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>